Atrial fibrillation device company AtriCure (Nasdaq:ATRC) is among five medical companies most likely to be targeted for an acquisition in the next year, according to a new analyst report.In addition to Cincinnati-area AtriCure, the other device companies identified by Canaccord Genuity analyst Jason Mills as likely near-term acquisition targets were: HeartWare, Spectranetics, Thoratec and Volcano, [...]

A U.S. Food and Drug Administration panel will review cardiac device maker AtriCure‘s (NASDAQ:ATRC) application for a label for the surgical treatment of atrial fibrillation.On Oct. 26, the FDA’s Circulatory System Devices Panel will review the Cincinnati-area device maker’s Premarket Approval Application (PMA) for its Synergy ablation system, according to a statement from West Chester, [...]

Medical device giants looking to boost their atrial fibrillation product portfolios would do well to take a long, hard look at cardiac device-maker AtriCure (NASDAQ:ATRC).Things have been looking up recently for Cincinnati-area AtriCure, and if the company hits a few near-term milestones its got in its sights, its price to a strategic acquirer will only [...]

Cardiology medical device maker AtriCure (NASDAQ:ATRC) expects to receive U.S. regulatory clearance for a new cryoablation system by the end of next quarter.The company’s cryoICE BOX system would use extreme cold to freeze cardiac tissue in order to correct abnormal electrical signals that cause heart arrhythmia.The system was launched during the second quarter in Europe [...]

Cardiac medical device maker AtriCure (NASDAQ:ATRC) sees big opportunity in a new “hybrid” procedure that treats atrial fibrillation with a combination of ablation from inside and outside of the heart.But the Cincinnati-area company will likely have to wait awhile before it begins to cash in on what CEO David Drachman has called a $2 billion [...]

The launch of a pivotal clinical trial next year for a “hybrid” procedure to treat atrial fibrillation patients will be an “inflection point” for cardiac surgical device maker AtriCure’s (NASDAQ:ATRC) U.S. business, its CEO said.The pivotal clinical trial, which could lead to regulatory approval of the hybrid procedure to treat atrial fibrillation and is called [...]

AtriCure (NASDAQ:ATRC) founder Michael Hooven‘s next project could change the way children are injected with vaccines.But you won’t hear that from him.Hooven politely declined to provide much detail on Cincinnati-based Enable Injections, saying that the company is still in its very early stages — though that could be changing soon.“In general, there are some very [...]

Cardiac surgical device maker AtriCure Inc. (NASDAQ:ATRC) has reported its first-ever profitable quarter as sales of its AtriClip device continue to climb. AtriCure’s better-than-expected financial results sent its shares up in early trading.

Investment bank Roth Capital Partners has upgraded shares of AtriCure Inc. (NASDAQ:ATRC) to “Buy” and raised its target price by nearly 30 percent.

Cardiac medical device maker AtriCure Inc. (NASDAQ:ATRC) has enrolled the first patient in a clinical trial designed to test a hybrid procedure on patients with persistent atrial fibrillation, a condition marked by irregular heart rhythm. The procedure being evaluated in the study combines AtriCure’s minimally invasive surgical ablation devices with a catheter-based ablation system from BioSense Webster, a Johnson & Johnson company.